GPX4 and cancer: BEBT-908, which is a dual PI3K/HDAC inhibitor, triggers a robust ferroptotic response in cancer cells, characterized by the reduction of SLC7A11 and GPX4, heightened lipid ROS and MDA levels, and activation of ferroptotic signaling.